Disease activity in rheumatoid arthritis and the risk of cardiovascular events

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1449-1455

  Solomon, D H ^a   Reed, G W ^b   Kremer, J M ^c,d   Curtis, J R ^e   Farkouh, M E ^f   Harrold, L R ^b   Hochberg, M C ^g   Tsao, P ^a   Greenberg, J D ^d,h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c Center for Rheumatology LLP   (United States)

^d Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^h NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOMODULATING AGENT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL DISEASE ACTIVITY INDEX; DIABETES MELLITUS; DISEASE ACTIVITY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; UNITED STATES; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT ANALYSIS; HYPERLIPIDEMIAS; INCIDENCE; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGISTER; SEVERITY OF ILLNESS INDEX; STROKE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COHORT STUDIES; CYCLOOXYGENASE 2 INHIBITORS; DIABETES MELLITUS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE; UNITED STATES;

EID: 84929908579     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39098     Document Type: Article

References (23)

1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D., Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, et al., Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003; 107: 1303-7.
3. Del Rincon I, Williams K, Stern MP, Freeman GL, O'Leary DH, Escalante A., Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2002; 48: 1833-40.
4. Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al., Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011; 70: 482-7.
5. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, et al., Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 2011; 108: 1362-70.
6. Barnabe C, Martin BJ, Ghali WA., Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011; 63: 522-9.
7. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al., Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 576-82.
8. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al., 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
9. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al., EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
10. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al., EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 325-31.
11. Haraoui B, Smolen JS, Aletaha D, Breedveld FC, Burmester G, Codreanu C, et al, the Treat to Target Taskforce. Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Ann Rheum Dis 2011; 70: 1999-2002.
12. Ridker PM, Thuren T, Zalewski A, Libby P,. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011; 162: 597-605.
13. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, et al., Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013; 166: 199-207.e15.
14. Kremer JM., The CORRONA database. Autoimmun Rev 2006; 5: 46-54.
15. Aletaha D, Smolen J., The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23 Suppl 39: S100-8.
16. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry, diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. URL: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm071627.pdf.
17. Braunwald E, Bristow MR., Congestive heart failure: fifty years of progress. Circulation 2000; 102: IV14-23.
18. Lin DY, Wei LJ, Ying Z., Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 1993; 80: 557-72.
19. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE., Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 722-32.
20. Arts EE, Popa C, Den Broeder AA, Semb AG, Toms T, Kitas GD, et al., Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis. Ann Rheum Dis 2015; 74: 668-74.
21. Solomon DH, Kremer J, Curtis JR, Hochberg MC, Reed G, Tsao P, et al., Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 2010; 69: 1920-5.
22. Arts EE, Fransen J, den Broeder AA, Popa CD, van Riel PL,. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2014. E-pub ahead of print.
23. Dixon WG, Watson KD, Lunt M, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al, on behalf of the British Society for Rheumatology Biologics Register. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56: 2905-12.